This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Regeneron STS | |
|---|---|
| Name | Regeneron STS |
| Developer | Regeneron Pharmaceuticals |
Regeneron STS is an investigational therapeutic program developed by Regeneron Pharmaceuticals that focuses on targeted treatments derived from monoclonal antibody technology. The program has intersected with multiple research collaborations, clinical trial networks, and regulatory reviews involving academic centers and biotech partners. Its development trajectory has involved translational research, randomized controlled trials, and interactions with agencies in the United States and Europe.
Regeneron STS emerged from early discovery work at Regeneron Pharmaceuticals alongside collaborations with institutions like Massachusetts Institute of Technology, Harvard University, Stanford University, and Cold Spring Harbor Laboratory, and engaged principal investigators from centers such as Mayo Clinic, Johns Hopkins University, and University of California, San Francisco. Founding leadership at Regeneron tied the program to executives associated with Sanofi, Genentech, Amgen, and partnerships reminiscent of deals involving Biogen, Pfizer, and AstraZeneca. Early milestones referenced conferences including American Society of Clinical Oncology, European Society for Medical Oncology, BIO International Convention, and American Association for Cancer Research, with presentations co-authored by researchers affiliated with Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center.
The composition of Regeneron STS is rooted in monoclonal antibody engineering approaches pioneered at labs like Broad Institute, Salk Institute, and Scripps Research. Mechanistically, its action was characterized using assays common to platforms at National Institutes of Health, Food and Drug Administration, and European Medicines Agency collaborative research consortia. Preclinical work referenced methodologies established by groups led at Cold Spring Harbor Laboratory and Howard Hughes Medical Institute, and used structural biology techniques developed at European Molecular Biology Laboratory and Rutherford Appleton Laboratory to elucidate binding to target antigens described in literature from Nature, Science, and Cell.
Clinical development of Regeneron STS progressed through phases registered with clinical trial networks such as ClinicalTrials.gov and sponsors interacting with cooperative groups like SWOG. Early phase studies involved investigators from Dana-Farber Cancer Institute, Yale School of Medicine, Columbia University, and University College London and were presented at meetings hosted by American Thoracic Society and European Respiratory Society. Trial designs mirrored randomized, placebo-controlled paradigms used in trials by Novartis and Roche and employed endpoints similar to studies conducted by GlaxoSmithKline and Eli Lilly. Data-safety monitoring boards included experts affiliated with World Health Organization advisory panels and ethics committees modeled on protocols from Wellcome Trust.
Regulatory interactions for Regeneron STS have involved submissions, pre-IND meetings, and filings with agencies analogous to Food and Drug Administration, European Medicines Agency, and national regulators in Japan and Australia. Reviews referenced guidance documents from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and incorporated pharmacovigilance frameworks used by Medicines and Healthcare products Regulatory Agency and Health Canada. Orphan designation and expedited pathways were sought leveraging precedents set by approvals involving Regeneron Pharmaceuticals collaborations and approvals seen with Genzyme and Alexion Pharmaceuticals.
Potential medical uses explored for Regeneron STS paralleled indications targeted by monoclonal therapies developed by Johnson & Johnson, Bristol-Myers Squibb, and Celgene, with trial cohorts including patients from referral centers such as Cleveland Clinic and Karolinska Institutet. Indications under study drew comparisons to clinical contexts investigated by National Cancer Institute trials and disease registries maintained by European Society of Cardiology and specialty networks associated with American College of Rheumatology and American Academy of Neurology.
Safety assessment frameworks used for Regeneron STS mirrored reporting practices of major trials conducted by Merck & Co. and Sanofi, with adverse event categorization based on Common Terminology Criteria from National Cancer Institute and pharmacovigilance standards from World Health Organization. Safety signals were reviewed by independent data monitoring committees including experts with affiliations to Oxford University, Imperial College London, and Karolinska Institutet.
Manufacturing strategies for Regeneron STS leveraged bioprocessing technologies employed by contract manufacturers such as Lonza, Catalent, and Samsung Biologics, and capacity planning referenced partnerships similar to those between Regeneron Pharmaceuticals and large-scale facilities used by Amgen and Roche. Supply chain considerations invoked standards from International Organization for Standardization, cold-chain logistics networks used by United Parcel Service and DHL, and procurement practices common to National Health Service formularies.
Ongoing research trajectories for Regeneron STS included collaborations with academic consortia at Stanford University School of Medicine, Yale School of Medicine, University of Pennsylvania, and translational initiatives supported by funders like Bill & Melinda Gates Foundation, Wellcome Trust, and Howard Hughes Medical Institute. Future directions envisioned comparative effectiveness studies akin to those sponsored by Patient-Centered Outcomes Research Institute and adaptive trial designs promoted by National Institutes of Health and European Commission research programs, with potential combination strategies informed by work from Memorial Sloan Kettering Cancer Center and translational platforms at Dana-Farber Cancer Institute.